Quantum Biopharma (NASDAQ:QNTM) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPS

Posted by Andrew Walz on Mar 28th, 2026

Quantum Biopharma (NASDAQ:QNTM – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49), Zacks reports.

Quantum Biopharma Price Performance

Shares of NASDAQ:QNTM opened at $4.77 on Friday. The company has a market cap of $18.22 million, a P/E ratio of -0.55 and a beta of 0.32. Quantum Biopharma has a 1 year low of $2.07 and a 1 year high of $38.25. The stock’s fifty day moving average price is $3.96 and its 200-day moving average price is $8.85.

Hedge Funds Weigh In On Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Virtu Financial LLC purchased a new stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned 0.27% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on QNTM. Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Quantum Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Quantum Biopharma presently has an average rating of “Sell”.

Get Our Latest Stock Analysis on QNTM

About Quantum Biopharma

(Get Free Report)

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.